{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:31:52Z","timestamp":1781019112816,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI 08 2210-01"],"award-info":[{"award-number":["U01 AI 08 2210-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1002\/jps.24295","type":"journal-article","created":{"date-parts":[[2015,1,11]],"date-time":"2015-01-11T23:33:52Z","timestamp":1421019232000},"page":"627-639","source":"Crossref","is-referenced-by-count":32,"title":["Glassy-State Stabilization of a Dominant Negative Inhibitor Anthrax Vaccine Containing Aluminum Hydroxide and Glycopyranoside Lipid A Adjuvants"],"prefix":"10.1016","volume":"104","author":[{"given":"Kimberly J.","family":"Hassett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Vance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Sahni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia A.","family":"Rabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan C.","family":"Cousins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Volkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Russell","family":"Middaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Mantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore W.","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/jps.24295_bb0005","series-title":"Temperature sensitivity of vaccines","author":"Quality, Safety and Standards team of the Department of Immunizations, Vaccines and Biologicals","year":"2006"},{"key":"10.1002\/jps.24295_bb0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","article-title":"Vaccine instability in the cold chain: Mechanisms, analysis and formulation strategies","volume":"42","author":"Kumru","year":"2014","journal-title":"Biologicals"},{"key":"10.1002\/jps.24295_bb0015","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1016\/j.vaccine.2007.02.052","article-title":"Freezing temperatures in the vaccine cold chain: A systematic literature review","volume":"25","author":"Matthias","year":"2007","journal-title":"Vaccine"},{"key":"10.1002\/jps.24295_bb0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4161\/hv.5.1.6494","article-title":"Characterization of the freeze sensitivity of a hepatitis B vaccine","volume":"5","author":"Chen","year":"2009","journal-title":"Hum Vaccines"},{"key":"10.1002\/jps.24295_bb0025","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/jps.22815","article-title":"Influence of formulation pH and suspension state on freezing-induced agglomeration of aluminum adjuvants","volume":"101","author":"Salnikova","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24295_bb0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.biologicals.2011.10.011","article-title":"Structural damages in adsorbed vaccines affected by freezing","volume":"41","author":"Kurz\u0105tkowski","year":"2013","journal-title":"Biologicals"},{"key":"10.1002\/jps.24295_bb0035","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijpharm.2011.05.022","article-title":"Stabilization of tetanus toxoid formulation containing aluminium hydroxide adjuvant against freeze- thawing","volume":"414","author":"Solanki","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.24295_bb0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.vaccine.2008.10.027","article-title":"Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants","volume":"27","author":"Braun","year":"2009","journal-title":"Vaccine"},{"key":"10.1002\/jps.24295_bb0045","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4161\/hv.4.5.5863","article-title":"Stabilization of measles virus for vaccine formulation","volume":"4","author":"Kissmann","year":"2008","journal-title":"Hum Vaccines"},{"key":"10.1002\/jps.24295_bb0050","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1002\/jps.22724","article-title":"Biophysical characterization and conformational stability of ebola and marburg virus-like particles","volume":"100","author":"Hu","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24295_bb0055","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1128\/CVI.00174-12","article-title":"Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant","volume":"19","author":"Wagner","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1002\/jps.24295_bb0060","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/jps.23375","article-title":"Physical characterization and formulation development of a recombinant pneumolysoid protein-based pneumococcal","volume":"102","author":"Hu","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24295_bb0065","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/jps.21543","article-title":"Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry","volume":"98","author":"Estey","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24295_bb0070","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/jps.23848","article-title":"Mechanism of a decrease in potency for the recombinant influenza A virus hemagglutinin H3 antigen during storage","volume":"103","author":"Hickey","year":"2014","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24295_bb0075","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ejpb.2013.03.029","article-title":"Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization","volume":"85","author":"Hassett","year":"2013","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1002\/jps.24295_bb0080","first-page":"11","article-title":"Forced degradation studies: An essential tool for the formulation development of vaccines","volume":"3","author":"Hasija","year":"2013","journal-title":"Vaccine"},{"key":"10.1002\/jps.24295_bb0085","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1023\/A:1012180707283","article-title":"Rational design of stable lyophilized protein formulations: Some practical advice","volume":"14","author":"Carpenter","year":"1997","journal-title":"Pharm Res"},{"key":"10.1002\/jps.24295_bb0090","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.2105\/AJPH.2008.151332","article-title":"Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: Results from a vaccine safety datalink study","volume":"99","author":"Nelson","year":"2009","journal-title":"Am J Public Health"},{"key":"10.1002\/jps.24295_bb0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1542\/peds.2010-0812","article-title":"Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses","volume":"127","author":"Widdice","year":"2011","journal-title":"Pediatrics"},{"key":"10.1002\/jps.24295_bb0100","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.drudis.2009.02.009","article-title":"The path to a successful vaccine adjuvant\u2014\u2018the long and winding road\u2019","volume":"14","author":"O\u2019Hagan","year":"2009","journal-title":"Drug Discov Today"},{"key":"10.1002\/jps.24295_bb0105","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nri3085","article-title":"Vaccines for the twenty-first century society","volume":"11","author":"Rappuoli","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1002\/jps.24295_bb0110","series-title":"Complete List of Vaccines Licensed for Immunization and Distribution in the US [Internet]","author":"U.S. Food and Drug Administration","year":"2012"},{"key":"10.1002\/jps.24295_bb0115","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/jps.21143","article-title":"Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying","volume":"97","author":"Clausi","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24295_bb0120","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1002\/jps.21390","article-title":"Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine","volume":"97","author":"Clausi","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24295_bb0125","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/jps.21433","article-title":"Influence of protein conformation and adjuvant aggregation on the effectiveness of aluminum hydroxide adjuvant in a model alkaline phosphatase vaccine","volume":"98","author":"Clausi","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24295_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"Coler","year":"2011","journal-title":"PloS ONE"},{"key":"10.1002\/jps.24295_bb0135","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1164\/rccm.201102-0209CI","article-title":"Anthrax infection","volume":"184","author":"Sweeney","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1002\/jps.24295_bb0140","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1126\/science.109563","article-title":"Dominant-negative mutants of a toxin subunit: An approach to therapy of anthrax","volume":"292","author":"Sellman","year":"2001","journal-title":"Science"},{"key":"10.1002\/jps.24295_bb0145","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF03402106","article-title":"Characterization of dominant-negative forms of anthrax protective antigen","volume":"9","author":"Yan","year":"2003","journal-title":"Mol Med"},{"key":"10.1002\/jps.24295_bb0150","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1128\/IAI.73.6.3408-3414.2005","article-title":"Combining anthrax vaccine and therapy: A dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines","volume":"73","author":"Aulinger","year":"2005","journal-title":"Infect Immun"},{"key":"10.1002\/jps.24295_bb0155","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.4161\/hv.25852","article-title":"Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccine","volume":"9","author":"Iver","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1002\/jps.24295_bb0160","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/prot.21432","article-title":"Multiple asparagine deamidation of Bacillus anthracis protective antigen causes charge isoforms whose complexity correlates with reduced biological activity","volume":"68","author":"Powell","year":"2007","journal-title":"Proteins"},{"key":"10.1002\/jps.24295_bb0165","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1128\/IAI.00863-12","article-title":"Use of site directed mutagenesis to model the effects of spontaneous deamidation on the immunogenicity of Bacillus anthracis protective antigen","volume":"81","author":"Verma","year":"2013","journal-title":"Infect Immun"},{"key":"10.1002\/jps.24295_bb0170","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/jps.23422","article-title":"Rapid deamidation of recombinant protective antigen when adsorbed on aluminum hydroxide gel correlates with reduced potency of vaccine","volume":"102","author":"D\u2019Souza","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24295_bb0175","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/meth.1999.0834","article-title":"Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines","volume":"19","author":"Baldridge","year":"1999","journal-title":"Methods"},{"key":"10.1002\/jps.24295_bb0180","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1023\/A:1018912417607","article-title":"Origin of the isoelectric heterogeneity of monoclonal immunoglobulin h1B4","volume":"10","author":"Tsai","year":"1993","journal-title":"Pharm Res"},{"key":"10.1002\/jps.24295_bb0185","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/jps.22458","article-title":"Trehalose: Current use and future applications","volume":"100","author":"Ohtake","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24295_bb0190","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1128\/JVI.02482-07","article-title":"A direct comparison of human papillomavirus type 16L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response","volume":"82","author":"Th\u00f6nes","year":"2008","journal-title":"J Virol"},{"key":"10.1002\/jps.24295_bb0195","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1016\/j.vaccine.2010.04.039","article-title":"Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection","volume":"28","author":"Jagu","year":"2010","journal-title":"Vaccine"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915302355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915302355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T14:39:28Z","timestamp":1566225568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915302355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0022354915302355"],"URL":"https:\/\/doi.org\/10.1002\/jps.24295","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}